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What does it take to develop one new 
cancer drug? 
•One billion dollars and 10-15 years 
•Drug discovery (5000-10,000 compounds) 
•Preclinical laboratory work (250 compounds) 
•Clinical trials in humans 
•FDA submission and approval 
How have cancer drugs changed? 
1970- 1990’s 
• Cytotoxic 
• Non-specific 
• Intravenous toxins 
• Highly toxic 
• DNA damaging 
 
2000 and beyond 
• Cytostatic 
• More selective 
• Oral/IV biologics 
• Well-tolerated 
• Targets the tumor 
and tumor 
environment 
Why do we 
need patient 
participation 
in clinical 
trials? 
Recently FDA approved oncology 
compounds 
•Everolimus 
•Bendamustine 
•Sunitinib 
•Sorafenib 
•Nilotinib 
• Ixabepilone 
•Temsirolimus 
•Lapatinib 
•Velcade 
• Imatinib 
• Vorinostat 
• Rituxan 
• Panitumumab 
• Lenalomide 
• Dasatinib 
• Decitabine 
• Cetuximab 
• Rituximab 
• Trastuzumab 
• Bevacizumab 
 
 
 
 
 
• Denosumab 
• Pazopanib 
• Sipuleucel-T 
• Eribulin 
• Ofatumumab 
• Ipilimumab 
• Cabazitaxel 
• Crizotinib 
 
FDA approved oncology drugs 2012-2013 
•Obinutuzumab 
•Pertuzumab 
•Nab-paclitaxel 
•Afatinib 
•Trametinib 
•Dabrafenib 
•Abiraterone 
•Cabozanitinib 
•Vandetanib 
 
 
• Omacetaxine 
• Regorafenib 
• Bosutinib 
• Enzalutamide 
• Ziv-aflibercept 
• Carfilzomib 
• Vismodegib 
• Axitinib 
• Ruxolitinib 
• Brentuximab 
• Vemurafenib 
 
 
Barriers to Clinical Trial Enrollment 
•Access 
•Education 
– Patient perceptions 
• “guinea pig” 
• “I don’t want a placebo” 
• “Will my insurance cover this?” 
– MD perceptions 
• Too time intensive 
• Too much paperwork 
•$$$$$ 
ONLY ~ 10% of 
all adult 
cancer 
patients 
participate in 
clinical trials! 
 
Locally advanced 
 
Resection 
 
Metastatic 
 
Pancreatic Cancer 
ADJUVANT 
THERAPY 
 
• RTOG 0848 
• HyperAcute 
Vaccine (CLOSED) 
 
• Gemcitabine/Nab-
paclitaxel/XRT 
• FOLFIRINOX and 
HyperAcute Vaccine 
 
PALLIATIVE THERAPY 
 
• Gemcitabine/cisplatin + 
birinapant 
 
 
Adjuvant Phase III Trial-RTOG 0848 
Principle Investigator: Adam Berger, MD 
HyperAcute®-Pancreas immunotherapy 
Adjuvant therapy (Gemcitabine alone or with 5-FU 
chemoradiation) with or without HyperAcute®-Pancreas 
(algenpantucel-L) immunotherapy in subjects who have 
undergone surgical resection 
Principal Investigator:  Harish Lavu, MD 
HyperAcute® Technology 
α(1,3)GT gene 
α(1,3)GT gene introduced into human cancer 
cells 
using viruses 
 
Selected human lung 
 cancer cell lines 
Selected human pancreatic  
cancer cell lines 
Locally Advanced Unresectable 
Pancreatic Adenocarcinoma 
 
Gemcitabine and Nab-Paclitaxel 
as a Promising Combination 
• Gemcitabine and Nab-Paclitaxel IV 
weekly x 3 with 1 week off 
vonHoff et al ASCO, 2013 
Patients with metastatic 
pancreas cancer receiving this 
doublet did better than the 
group receiving gemcitabine 
alone. 
 
Upcoming Gem/Paclitaxel Trial for Locally 
Advanced Pancreas Cancer 
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Principal Investigator:  Voichita Bar-Ad, MD 
FOLFIRINOX as a Promising Regimen 
NEJM 364 (19): 1817-1825, 2011 
5Fluorouracil 
Oxaliplatin 
Leucovorin 
Irinotecan 
IV every 2 weeks 
Patients with metastatic 
pancreas cancer did better 
than the group receiving 
gemcitabine alone. 
Open Trial of FOLFIRINOX With 
or Without HyperAcute®- 
Pancreas Immunotherapy Trial 
for Locally Advanced Pancreas 
Cancer 
Study Schema 
Principal Investigator:  Harish Lavu, MD 
Metastatic Pancreas Cancer 
Birinapant 
• Programmed cell death is 
called apoptosis. 
 
• Cancer cells circumvent 
apoptosis and continue to grow. 
 
• TL32711 or birinapant, 
antagonizes the cancer cells’ 
inhibitors of apoptosis and can 
make the chemotherapy work 
better at killing cancer cells. 
Gemcitabine/Cisplatin + TL 327811 (Birinapant)  
Pancreas Cancer 
Table 1b: Dose escalation scheme of TL32711 in combination with gemcitabine plus cisplatin (Part A2) (each 
cycle is 21 days) 
Dose Level TL32711 (iv) 
Gemcitabine (iv) once 
weekly x 2 weeks (Day 
1 and 8) 
Cisplatin (iv) once 
every 3 weeks 
(Day 1) 
-A1 
17 mg/m2  
once weekly x 2 
1000 mg/m2  75 mg/m2 
A1  
22 mg/m2 
once weekly x 2 
A2 
26 mg/m2 
once weekly x 2 
A3 
35 mg/m2 
once weekly x 2 
Principal Investigator:  Nancy Lewis, MD 
“Enrollment in a 
clinical trial is the 
best management 
for patients with 
cancer” 
National Comprehensive 
Cancer Network Guidelines 
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